A simple blood test could reduce the need for intrusive surgery when determining the best course of treatment for patients with a specific type of brain tumour. Researchers at the Brain Tumour Research Centre of Excellence have discovered a biomarker (Fibulin-2) that helps to distinguish whether meningioma – the most common form of adult primary brain tumour – is grade I or grade II. The grading is significant because lowergrade tumours can sometimes remain dormant for long periods, not requiring high risk surgery or harsh treatments. In total, 70–85% of meningioma cases are lower grade so, if the blood test – or liquid biopsy – is carried out, these patients may well be spared surgery or radiotherapy.
Annual Review 2021: Health and Care Research
Advances and discoveries in health and care research
